116 related articles for article (PubMed ID: 38494798)
1. [Return of Individual Genomic Results to Germline Pathogenic Variant Carriers of Hereditary Cancer in Population Based Cohort Study].
Ohneda K
Gan To Kagaku Ryoho; 2024 Mar; 51(3):231-236. PubMed ID: 38494798
[TBL] [Abstract][Full Text] [Related]
2. Returning individual genomic results to population-based cohort study participants with BRCA1/2 pathogenic variants.
Ohneda K; Hamanaka Y; Kawame H; Fuse N; Nagami F; Suzuki Y; Yamaguchi-Kabata Y; Shimada M; Masamune A; Aoki Y; Ishida T; Yamamoto M
Breast Cancer; 2023 Jan; 30(1):110-120. PubMed ID: 36161580
[TBL] [Abstract][Full Text] [Related]
3. Association of Rare Pathogenic DNA Variants for Familial Hypercholesterolemia, Hereditary Breast and Ovarian Cancer Syndrome, and Lynch Syndrome With Disease Risk in Adults According to Family History.
Patel AP; Wang M; Fahed AC; Mason-Suares H; Brockman D; Pelletier R; Amr S; Machini K; Hawley M; Witkowski L; Koch C; Philippakis A; Cassa CA; Ellinor PT; Kathiresan S; Ng K; Lebo M; Khera AV
JAMA Netw Open; 2020 Apr; 3(4):e203959. PubMed ID: 32347951
[TBL] [Abstract][Full Text] [Related]
4. Novel candidates of pathogenic variants of the BRCA1 and BRCA2 genes from a dataset of 3,552 Japanese whole genomes (3.5KJPNv2).
Tokunaga H; Iida K; Hozawa A; Ogishima S; Watanabe Y; Shigeta S; Shimada M; Yamaguchi-Kabata Y; Tadaka S; Katsuoka F; Ito S; Kumada K; Hamanaka Y; Fuse N; Kinoshita K; Yamamoto M; Yaegashi N; Yasuda J
PLoS One; 2021; 16(1):e0236907. PubMed ID: 33428613
[TBL] [Abstract][Full Text] [Related]
5. Germline mutational variants of Turkish ovarian cancer patients suspected of Hereditary Breast and Ovarian Cancer (HBOC) by next-generation sequencing.
Tuncer SB; Celik B; Erciyas SK; Erdogan OS; Gültaslar BK; Odemis DA; Avsar M; Sen F; Saip PM; Yazici H
Pathol Res Pract; 2024 Feb; 254():155075. PubMed ID: 38219492
[TBL] [Abstract][Full Text] [Related]
6. Prevalence of mutations in BRCA and MMR genes in patients affected with hereditary endometrial cancer.
Vietri MT; D'Elia G; Caliendo G; Casamassimi A; Federico A; Passariello L; Cioffi M; Molinari AM
Med Oncol; 2021 Jan; 38(2):13. PubMed ID: 33484353
[TBL] [Abstract][Full Text] [Related]
7. Prevalence of genetic susceptibility for breast and ovarian cancer in a non-cancer related study population: secondary germline findings from a Swiss single centre cohort.
Kraemer D; Azzarello-Burri S; Steindl K; Boonsawat P; Zweier M; Dedes KJ; Joset P; Fink D; Rauch A
Swiss Med Wkly; 2019 Aug; 149():w20092. PubMed ID: 31422574
[TBL] [Abstract][Full Text] [Related]
8. Germline mutation prevalence in individuals with pancreatic cancer and a history of previous malignancy.
Dudley B; Karloski E; Monzon FA; Singhi AD; Lincoln SE; Bahary N; Brand RE
Cancer; 2018 Apr; 124(8):1691-1700. PubMed ID: 29360161
[TBL] [Abstract][Full Text] [Related]
9. Population-based genetic testing of asymptomatic women for breast and ovarian cancer susceptibility.
Rowley SM; Mascarenhas L; Devereux L; Li N; Amarasinghe KC; Zethoven M; Lee JEA; Lewis A; Morgan JA; Limb S; Young MA; James PA; Trainer AH; Campbell IG
Genet Med; 2019 Apr; 21(4):913-922. PubMed ID: 30254378
[TBL] [Abstract][Full Text] [Related]
10. [Current clinical issues and recent trends in hereditary breast and ovarian cancer in Japan-genetic testing for HBOC and risk-reducing surgery].
Arai M; Iwase T; Takazawa Y; Takeshima N
Gan To Kagaku Ryoho; 2014 Nov; 41(11):1333-9. PubMed ID: 25434434
[TBL] [Abstract][Full Text] [Related]
11. Co-occurrence of germline pathogenic variants for different hereditary cancer syndromes in patients with Lynch syndrome.
Ferrer-Avargues R; Castillejo MI; Dámaso E; Díez-Obrero V; Garrigos N; Molina T; Codoñer-Alejos A; Segura Á; Sánchez-Heras AB; Castillejo A; Soto JL
Cancer Commun (Lond); 2021 Mar; 41(3):218-228. PubMed ID: 33630411
[TBL] [Abstract][Full Text] [Related]
12. Germline multigene panel testing of patients with endometrial cancer.
Kral J; Jelinkova S; Zemankova P; Vocka M; Borecka M; Cerna L; Cerna M; Dostalek L; Duskova P; Foretova L; Havranek O; Horackova K; Hovhannisyan M; Chvojka S; Kalousova M; Kosarova M; Koudova M; Krutilkova V; Machackova E; Nehasil P; Novotny J; Otahalova B; Puchmajerova A; Safarikova M; Slama J; Stranecky V; Subrt I; Tavandzis S; Zikan M; Zima T; Soukupova J; Kleiblova P; Kleibl Z; Janatova M
Oncol Lett; 2023 Jun; 25(6):216. PubMed ID: 37153042
[TBL] [Abstract][Full Text] [Related]
13. Cancer Predisposition Cascade Screening for Hereditary Breast/Ovarian Cancer and Lynch Syndromes in Switzerland: Study Protocol.
Katapodi MC; Viassolo V; Caiata-Zufferey M; Nikolaidis C; Bührer-Landolt R; Buerki N; Graffeo R; Horváth HC; Kurzeder C; Rabaglio M; Scharfe M; Urech C; Erlanger TE; Probst-Hensch N; Heinimann K; Heinzelmann-Schwarz V; Pagani O; Chappuis PO
JMIR Res Protoc; 2017 Sep; 6(9):e184. PubMed ID: 28931501
[TBL] [Abstract][Full Text] [Related]
14. Prevalence of germline variants in consensus moderate-to-high-risk predisposition genes to hereditary breast and ovarian cancer in BRCA1/2-negative Brazilian patients.
Gomes R; Spinola PDS; Brant AC; Matta BP; Nascimento CM; de Aquino Paes SM; Bonvicino CR; Dos Santos ACE; Moreira MAM
Breast Cancer Res Treat; 2021 Feb; 185(3):851-861. PubMed ID: 33128190
[TBL] [Abstract][Full Text] [Related]
15. Pediatric reporting of genomic results study (PROGRESS): a mixed-methods, longitudinal, observational cohort study protocol to explore disclosure of actionable adult- and pediatric-onset genomic variants to minors and their parents.
Savatt JM; Wagner JK; Joffe S; Rahm AK; Williams MS; Bradbury AR; Davis FD; Hergenrather J; Hu Y; Kelly MA; Kirchner HL; Meyer MN; Mozersky J; O'Dell SM; Pervola J; Seeley A; Sturm AC; Buchanan AH
BMC Pediatr; 2020 May; 20(1):222. PubMed ID: 32414353
[TBL] [Abstract][Full Text] [Related]
16. Identification of germline pathogenic variants in DNA damage repair genes by a next-generation sequencing multigene panel in BRCAX patients.
Rodríguez-Balada M; Roig B; Melé M; Albacar C; Serrano S; Salvat M; Querol M; Borràs J; Martorell L; Gumà J
Clin Biochem; 2020 Feb; 76():17-23. PubMed ID: 31786208
[TBL] [Abstract][Full Text] [Related]
17. The uptake of presymptomatic genetic testing in hereditary breast-ovarian cancer and Lynch syndrome: a systematic review of the literature and implications for clinical practice.
Menko FH; Ter Stege JA; van der Kolk LE; Jeanson KN; Schats W; Moha DA; Bleiker EMA
Fam Cancer; 2019 Jan; 18(1):127-135. PubMed ID: 29846880
[TBL] [Abstract][Full Text] [Related]
18. Germline EMSY sequence alterations in hereditary breast cancer and ovarian cancer families.
Määttä KM; Nurminen R; Kankuri-Tammilehto M; Kallioniemi A; Laasanen SL; Schleutker J
BMC Cancer; 2017 Jul; 17(1):496. PubMed ID: 28738860
[TBL] [Abstract][Full Text] [Related]
19. Genotype-first approach to the detection of hereditary breast and ovarian cancer risk, and effects of risk disclosure to biobank participants.
Leitsalu L; Palover M; Sikka TT; Reigo A; Kals M; Pärn K; Nikopensius T; Esko T; Metspalu A; Padrik P; Tõnisson N
Eur J Hum Genet; 2021 Mar; 29(3):471-481. PubMed ID: 33230308
[TBL] [Abstract][Full Text] [Related]
20.
Rofes P; Del Valle J; Torres-Esquius S; Feliubadaló L; Stradella A; Moreno-Cabrera JM; López-Doriga A; Munté E; De Cid R; Campos O; Cuesta R; Teulé Á; Grau È; Sanz J; Capellá G; Díez O; Brunet J; Balmaña J; Lázaro C
Genes (Basel); 2021 Jan; 12(2):. PubMed ID: 33498765
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
